Andrew J. Murphy, Co-Chief Scientific Officer of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), filed a Form 4 on November 18, 2026, disclosing transactions in common stock occurring on November 16 and November 17, 2026, executed under a Rule 10b5-1(c) plan.
Key Highlights
- Option exercise: Murphy exercised a non-qualified stock option for 17,000 shares of common stock on November 16, 2026, at an exercise price of $381.92 per share.
- Tax withholding disposition: 11,989 shares were disposed of on November 16, 2026, at $960.02 per share, coded as an "F" (payment of exercise price or tax liability) transaction.
- Open-market sales: A total of 4,671 shares were sold across multiple transactions on November 17, 2026, at prices ranging from $949.69 to $964.36 per share.
- Resulting direct ownership: Following all reported transactions, Murphy directly owned 46,779 shares of common stock as of the last reported transaction on November 17, 2026.
- Indirect holdings: The filing also reports 4,414 shares held indirectly through a 401(k) plan.
- 10b5-1 plan: According to the filing, all dispositions and acquisitions were made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 7, 2026.
Murphy's Option Exercise and Share Sales at Regeneron in November 2026
According to the filing, on November 16, 2026, Murphy acquired 17,000 shares through the exercise of a non-qualified stock option at an exercise price of $381.92 per share, with an expiration date of December 16, 2026. On the same date, 11,989 shares were disposed of at $960.02 per share in a transaction coded "F," which the form associates with the payment of a tax liability or exercise price. Following these two transactions, Murphy's direct beneficial ownership stood at 51,790 shares.
On November 17, 2026, Murphy sold a total of 4,671 shares across sixteen separate transactions. The filing reports each tranche at a volume-weighted average price, with individual sale prices ranging from $949.69 for 93 shares up to $964.36 for 340 shares in the final tranche. For several tranches, the filing notes that the reported price is a volume-weighted average and that full detail on individual prices within each range is available upon request by Commission staff, the company, or a security holder.
All transactions disclosed in the filing were made pursuant to a Rule 10b5-1(c) plan adopted on May 7, 2026, according to the explanation of responses. After all reported transactions, Murphy's direct ownership totaled 46,779 shares, with an additional 4,414 shares held indirectly through a 401(k) plan, as disclosed in the filing.
What Was Disclosed
The filing reports Andrew J. Murphy's exercise of 17,000 stock options, a related tax-withholding share disposition of 11,989 shares, and open-market sales of 4,671 shares over November 16-17, 2026, all under a pre-established 10b5-1 plan.



Please wait processing your request...